Key result
Empagliflozin shows no difference in 6-month bacteriuria or UTI risk versus dapagliflozin in HFpEF.
Why the study?
Sodium–glucose cotransporter 2 inhibitors are guideline-directed therapy for HFpEF, but comparative genitourinary safety data for dapagliflozin and empagliflozin in HFpEF-treated populations remain limited.
Does empagliflozin compared to dapagliflozin alter the 6-month risk of symptomatic urinary tract infection, asymptomatic bacteriuria, and other genitourinary adverse events in adults with heart failure with preserved ejection fraction?
Cohort (n=239)
No
Does empagliflozin compared to dapagliflozin alter the 6-month risk of symptomatic urinary tract infection, asymptomatic bacteriuria, and other genitourinary adverse events in adults with heart failure with preserved ejection fraction?
In a small single-center retrospective cohort of HFpEF patients, there was no statistically detectable difference in 6-month genitourinary adverse events, symptomatic UTI, or asymptomatic bacteriuria between dapagliflozin and empagliflozin, though wide confidence intervals preclude definitive conclusions on equivalence.
Background Sodium–glucose cotransporter 2 inhibitors are guideline-directed therapy for heart failure with preserved ejection fraction (HFpEF), but comparative genitourinary safety data for dapagliflozin and empagliflozin in HFpEF-treated populations remain limited. Objective To compare 6-month symptomatic urinary tract infection (UTI), asymptomatic bacteriuria, and other genitourinary adverse events among patients newly initiated on dapagliflozin or empagliflozin for HFpEF. Methods This retrospective, single-centre comparative cohort study included 239 adults with physician-documented HFpEF retained after a requirement for at least 6 months of continuous follow-up: 113 received dapagliflozin 10 mg once daily and 126 received empagliflozin 10 mg once daily. The original outcome of any documented bacteriuria/UTI was separated into symptomatic UTI and asymptomatic bacteriuria. Risk differences and 95% confidence intervals were calculated; a multivariable logistic model of the original documented bacteriuria/UTI composite adjusted for age, sex, and baseline estimated glomerular filtration rate (eGFR). Results Any documented bacteriuria/UTI occurred in 21/113 (18.6%) dapagliflozin-treated participants and 25/126 (19.8%) empagliflozin-treated participants. Symptomatic UTI occurred in 4/113 (3.5%) and 5/126 (4.0%), respectively; 17/113 (15.0%) and 20/126 (15.9%) had documented asymptomatic bacteriuria. The risk difference for the composite, calculated as empagliflozin minus dapagliflozin, was 1.3 percentage points (95% CI −8.9 to 11.2). The adjusted odds ratio was 1.62 (95% CI 0.76–3.45; p = 0.208). Other genitourinary events were uncommon and estimates were imprecise. Conclusions No statistically detectable between-group difference was found in symptomatic UTI, asymptomatic bacteriuria, or the original composite outcome. Confidence intervals were wide and compatible with clinically meaningful differences in either direction. These exploratory findings require confirmation in prospective multicentre studies with standardized culture ascertainment and complete follow-up.
No takes yet. Share an insight, caveat, or question.
Dănău et al. (2026) conducted a cohort in Heart Failure with Preserved Ejection Fraction (n=239). Empagliflozin 10 mg once daily vs. Dapagliflozin 10 mg once daily was evaluated on Any documented bacteriuria or urinary tract infection within 6 months (OR 1.62, 95% CI 0.76-3.45, p=0.208). Empagliflozin did not significantly differ from dapagliflozin in 6-month risk of documented bacteriuria/UTI in HFpEF patients (19.8% vs 18.6%; adjusted OR 1.62, 95% CI 0.76-3.45, p=0.208).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: